In a report published Monday, Citigroup analyst Robin Shoemaker reiterated a Buy rating on IPC The Hospitalist Company IPCM, and raised the price target from $68.00 to $70.00.
In the report, Citigroup noted, “DRC reported 2Q13 EPS of $0.69 compared to our $0.57 estimate and the $0.57 consensus. Revenues of $805M were well below our $845M estimate and the $837M consensus estimate. Full-year 2013 operating income guidance was lowered to $430M-$450M (from the low end of the $450M-$530M initial range previously) while full-year 2013 revenue guidance was lowered to $3.4B-$3.6B (from $3.5B-$3.7B previously). We have reduced our EPS estimates from $3.30 to $3.15 in 2013, from $4.30 to $4.10 in 2014, and from $5.25 to $5.00 in 2015. Despite the lowered estimates, we reiterate our Buy rating on DRC and have increased our price target from $68 to $70 due to its strong and sustained long-term growth prospects across the energy value chain.”
IPC The Hospitalist Company closed on Friday at $60.74.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in